



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin Appoints Fabrice Egros as President of its Asia-Pacific Business

Mumbai, October 23, 2015: Pharma major Lupin today announced the appointment of Fabrice Egros as President, Asia Pacific and Japan. He will be based in Tokyo, Japan. Fabrice has over 25 years of experience within the global pharmaceutical industry, having worked in leadership roles encompassing P&L management for new markets, mergers & acquisitions, marketing & commercial, global strategy and business development as well as global clinical development, regulatory and manufacturing. He will be responsible for Lupin's growth and development across key markets such as Japan, Australia, the Philippines, South East Asia and new markets in the rest of the ASEAN region. Prior to joining Lupin, Fabrice was with NovaMedica where he was the Deputy CEO/ COO and instrumental in setting up an integrated new pharmaceutical business. Before NovaMedica, he has worked with global majors such as UCB, Sanofi and Parke Davis in various global and regional capacities.

Fabrice holds a Degree in Pharmacy, a MS in clinical pharmacology and a Doctorate in Pharmaceutical Sciences from the University of Paris (School of Medicine and Pharmacy) as well as a MBA from Schiller University. He has also completed Advanced Management Program from Harvard University.

Commenting on the appointment, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, *"We are delighted to have Fabrice join the Lupin family. His deep knowledge of the Asia-Pacific markets will be invaluable as we consolidate and grow our business in the region. This region is the third largest revenue contributor for us globally and I believe that Fabrice's experience will help Lupin achieve its growth plans for the Asia Pacific region, and help us scale the business to new heights."*

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th – IMS Health).

For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively.

Please visit <http://www.lupin.com> for more information.

You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098

Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupin.com

or

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupin.com

[Safe Harbor Statement](#)